Elcelyx Secures $40 Million for Diabetes Treatment

Elcelyx Therapeutics, a San Diego-based company, raised $20 million in the first tranche of a $40 million series E round led by Sailing Capital, a Hong Kong-based private equity firm. Elcelyx expects to receive the $20 million second tranche in 2016. The funds will support a large Phase IIb, dose-ranging clinical trial to evaluate the company’s lead therapy Metformin DR. Concurrent with the financing, Liang Tsui of Sailing Capital joined Elcelyx's board. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.